Phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) is
generated
by phosphatidylinositol 4-phosphate 5-kinases (PIP5Ks) from phosphatidylinositol
4-phosphate (PI4P). Structurally diverse and selective inhibitors
against PIP5Ks are required to further elucidate the therapeutic potential
for PIP5K inhibition, although the effects of PIP5K inhibition on
various diseases and their symptoms, such as cancer and chronic pain,
have been reported. Our medicinal chemistry efforts led to novel and
potent PIP5K1C inhibitors. Compounds 30 and 33 not only showed potent activity but also demonstrated low total
clearance in mice and high levels of kinase selectivity. These compounds
might serve as tools to further elucidate the complex biology and
therapeutic potential of PIP5K inhibition.